CureVac
Dr. Sandra C. Wullich is a highly skilled professional in the field of molecular microbiology and biotechnology, currently serving as the Strategy & Program Realization Manager for Technical Operations at CureVac since June 2021. With experience as a Project Manager in Analytical Development and an Associate Project Manager for CMC Program Management, Dr. Wullich has played a key role in various drug product projects, overseeing transitions from "commit to candidate" to "Clinical Trial Material (CTM) readiness." Prior to this, Dr. Wullich was a PhD candidate at Westfälische Wilhelms-Universität Münster, focusing on protein engineering and a range of related techniques. Additional academic experiences include internships and auxiliary research roles at prestigious institutions, culminating in degrees from the University of Münster and the University of Freiburg.
This person is not in any teams
This person is not in any offices
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.